Immune Targeting of Prostate Cancer

摘要

Immune targeting of prostate cancer has now reached a tipping point in terms of agents and strategies leading to patient benefit, with great potential for the use of vaccines in combination with chemotherapy, radiation, hormone therapy, and/or small molecule-targeted therapeutic agents. The Provenge vaccine (sipuleucel-T) was recently approved by the U.S. Food and Drug Administration (FDA) for use in patients with metastatic castrate-resistant prostate cancer (mCRPC). Randomized phase III trial results demonstrated a median overall survival of 25.8 months compared with 21.7 months for placebo (A 4.1 months).